Merck Animal Health, NEADS launch educational service dog campaignMay 22, 2019A new educational campaign highlights the importance of keeping service dogs healthy from fleas and ticks. Through Bravecto Cares, Merck Animal Health will donate a portion of every Bravecto sale to National Education for Assistance Dog Services (NEADS) World Class Service Dogs from now until June 30. The funds raised will be used to support the training of NEADS Service Dogs. "Merck Animal Health knows how important it is to protect our pets, especially those that work for us," says Mark Pelham, DVM, companion animal professional services, Merck Animal Health. "More than just a nuisance, fleas and ticks can carry illness, such as Lyme disease, to our pets and our families. We are proud to collaborate with NEADS, an organization that shares our dedication to keeping pets healthy as part of their extensive service dog training program." According to NEADS, being in top health is a major factor for a world-class service dog. "The health of our dogs is as important as their task training—if they are not at optimal health, they will not be at ideal performance and can potentially put their handlers at risk," says Cathy Zemaitis, NEADS director of development. As part of the campaign, Merck is …
SPONSORED CONTENTOne dose protects for 12 months.One ProHeart® 12 (moxidectin) injection puts compliance in your control. + Get started
FDA issues alert for isoxazoline class of flea, tick productsSeptember 21, 2018The U.S. Food and Drug Administration is alerting veterinarians and pet owners of the potential for neurologic adverse events in dogs and cats when treated with isoxazoline class flea and tick products, including Bravecto, Nexgard, and Simparica. Data received by the agency as part of its routine post-marketing activities indicates that some animals receiving Bravecto, Nexgard, or Simparica have experienced adverse events such as muscle tremors, ataxia, and seizures, said the FDA in a statement. Credelio, another isoxazoline class product, recently received FDA approval. These products are approved for the treatment and prevention of flea infestations, and the treatment and control of tick infestations. The FDA said it is working with manufacturers of isoxazoline products to include new label information to highlight neurologic events, as they were seen consistently across the isoxazoline class of products. These products continue to be safe and effective for the majority of animals, said the FDA, adding that it carefully reviewed studies and other data on Bravecto, Credelio, Nexgard, and Simparica prior to approval. The agency is asking the manufacturers to change product labeling in order to provide veterinarians and pet owners with the information they need to make treatment decisions …
